Overview

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.
Phase:
Phase 3
Details
Lead Sponsor:
Ardea Biosciences, Inc.
Treatments:
Lesinurad